Form 4: Health Catalyst General Counsel Sells Over 6,000 Shares Under Pre-Arranged Trading Plan

Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), has sold 6,057 shares of common stock for approximately $23,890, executed under a Rule 10b5-1 trading plan.

Summary

• Benjamin Landry, the General Counsel of Health Catalyst, Inc. (HCAT), reported the sale of 6,057 shares of the company's common stock.
• The transaction occurred on June 5, 2025, at a price of $3.9443 per share.
• The total value of the shares sold amounts to approximately $23,890.79.
• Following this transaction, Mr. Landry beneficially owns 151,125 shares of Health Catalyst common stock.
• The sale was conducted pursuant to a pre-arranged Rule 10b5-1 trading plan, which was adopted by Mr. Landry on March 1, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the fact that it's executed under a Rule 10b5-1 plan mitigates any negative implications, as it indicates a pre-scheduled transaction rather than a reaction to recent events or new information.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it might suggest a lack of confidence, although this is mitigated by the pre-planned nature of the sale.

Risks

• While the sale was pre-planned, significant insider selling over time could potentially signal concerns about future company performance or valuation, which is a general risk associated with such transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's pre-planned stock sale within the healthcare technology sector.

Stakeholder Impact

• Shareholders: May observe the insider sale, but the 10b5-1 plan typically reduces concerns about the sale's implications for company performance.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Health Catalyst, HCAT, Benjamin Landry, General Counsel, Insider Sale, SEC Form 4, 10b5-1 Plan, Stock Transaction, Beneficial Ownership, Equity Securities